SCHEMBL5651888

SCHEMBL5651888

CCOC(=O)c1sc2c(ccc(=O)n2-c2ccccc2)c1-c1ccccc1C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.44
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
GAA P10253 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
POLB P06746 1/20 0.40
MDM2 Q00987 1/20 0.40
KDM4E B2RXH2 3/20 0.39
NPSR1 Q6W5P4 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
RECQL P46063 1/20 0.38
MAT2A P31153 1/20 0.38
HPGD P15428 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
HSD17B10 Q99714 1/20 0.36
DHODH Q02127 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5654208 0.87 MAPT (0.47) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL5651789 0.87 MAPT (0.48) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL5650462 0.85 MAPT (0.47) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL5649140 0.85 MAPT (0.47) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL5654243 0.85 MAPT (0.46) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL5650136 0.84 MAPT (0.51) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL5650927 0.83 MAPT (0.44) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL5651307 0.83 DHODH (0.47) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL5650443 0.82 MAPT (0.50) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL5649662 0.82 MAPT (0.43) MAPTALDH1A1MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176215-B2 Bicyclic oxopyridine and oxopyrimidine derivatives CELLTECH R&D LIMITED (GB) 2007-02-13 US disclosed
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives UCB PHARMA S.A. (BE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254200-A1 Bicyclic oxopyridine and oxopyrimidine derivatives MAPK1, ALK, NAT1 MAPT 3795/4885ALDH1A1 1498/4885MEN1 4697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.